Benin vs Colombia: Average cost of drugs for extensively drug-resistant tuberculosis
Benin
6,274 constant 2022 US$
in 2024
Colombia
5,370 constant 2022 US$
in 2024
Benin rank
6th
Colombia rank
8th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Benin
- Colombia
How they compare
Benin currently reports 6,274 constant 2022 US$ against 5,370 constant 2022 US$ in Colombia, a difference of 904 constant 2022 US$.
That makes Benin's figure about 1.2 times Colombia's.
Across all 6 years both countries report, Benin has been ahead every year.
Benin ranks 6th and Colombia ranks 8th of 56 countries.
Benin has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Benin | Colombia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,550 constant 2022 US$ | 2,800 constant 2022 US$ | 2,750 constant 2022 US$ | Benin |
| 2020s | 6,274 constant 2022 US$ | 1,658 constant 2022 US$ | 4,616 constant 2022 US$ | Benin |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Benin or Colombia?
- Benin, at 6,274 constant 2022 US$ against 5,370 constant 2022 US$ in Colombia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Benin and Colombia?
- 904 constant 2022 US$, with Benin ahead.
- How many years of comparable data are there for Benin and Colombia?
- 6 years are reported by both, from 2019 to 2024.
- How do Benin and Colombia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Benin ranks 6th and Colombia ranks 8th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.